Dr. Manuela Neuman, University of Toronto, Canada
- Mon Sep 23 8:00 AM - 9:00 AM Imperial AR2305: Monitoring Biological Therapies (Interferon-Therapies Or Anti-Tumor Necrosis Factor Therapies)
- Thu Sep 26 8:00 AM - 9:00 AM Imperial AR2604: Alcohol And Drug Use; A Deadly Combination
Dr. Neuman is Assistant Professor of Pharmacology and Toxicology, and Associated Global Health at Faculty of Medicine, The University of Toronto. She is the founder and CEO In Vitro Drug Safety and Biotechnology, Toronto. Dr. Neuman holds a Ph.D., in Physiology and Pharmacology from Faculty of Medicine Tel-Aviv University, Israel. Dr.Neuman also completed her post-doctoral fellowship in Clinical Chemistry, Hepatology, Immunology, Gastroenterology and Virology, as well as a Post Doctoral Fellowship in Gastroenterology and Pharmacology at the University of Toronto, Toronto, Canada. Dr. Neuman has published extensively in the areas of therapeutic and drug of (use and misuse) monitoring, new biologic and their monitoring in clinical practice, pharmacogenetic and immunopharmacogentic clinical applications, drug-induced liver and skin adverse reactions, liver immunology, hepatocellular carcinoma and inflammatory bowel disease. Since 1992, she is a member of the IATDMCT actively participating at all the meetings. Dr. Neuman has served the University of Toronto in many capacities including Head of the In Vitro Biotechnology Platform. Clinical chemists, academic researchers, as well as, pharmaceutical industries’ leaders are aware of the need for greater competence in the molecular diagnosis of diseases and possible monitoring of treatments by using the specific molecular diagnostic biomarkers. Dr. Neuman has been committed to developing innovative diagnostic products that address prevention, diagnosis and treatment of diseases, thus enhancing people’s health and quality of life. Dr. Neuman has patented efficient quantitative kit to diagnose and monitor the severity of diseases that affect the central nervous system and the liver. Dr. Neuman’s research activities include the role of immunopharmacology in evaluation of safety profiles of different drugs. Moreover alternative options for therapeutic class are provided. International collaborators embrace her interdisciplinary research. She has a renowned record in promoting of hepatic safety of agents in patients with underlying liver disease in different scientific national and international fora. Another important subject of Dr. Neuman’s research is efficacy of therapies, expression of pathogen recognition receptors and signaling pathways involved in liver injury. Other subjects include the role of immune system in viral hepatitis, interactions of cytokines and chemokines receptors as a mechanism regulating inflammation and steatosis in the liver, the role of immunity as well as fibrogenesis. Dr. Neuman uses therapeutic and drug monitoring techniques as key to personalized medicine that allows earlier detection of diseases. Dr. Neuman is an organizer of international symposia on the basic and translational research. In vitro modeling technology allows accurate decision making at critical junctures in drug development. Moreover, her translational research skill permits developing a panel of assays to assess potential clinical toxicity.